Category Archives: Myocardial Infarction

OBJECTIVE: To determine the frequency of no reperfusion therapy, its reasons, hospital management and intermediate-term outcome s of ST- elevation my ocardial in farction patients . The retrospective ambi-directional observational study was conducted at Tabba Heart Institute, Karachi, and comprised record of ST-elevationmyocardial infarctionpatients without immediate reperfusion therapy with symptom onset time of 12 hours who presented between January 2013 and December 2017. Prospective follow-up of all patients was performed till June 2018. Continue reading →

Zion Market Research added a new report on Myocardial Infarction Treatment Market Size & Share Research Report, 2018-2024" in its database. The Myocardial Infarction Treatment Market report analysis includes sales & revenue, industry size & Share, analysis by value & volume, Trends, growth prospects & major companies. Continue reading →

PHILADELPHIA Even the sickest of patients with acute heart failure (HF) can be safely started on sacubitril/valsartan (Entresto, Novartis) in the intensive-care unit (ICU) as part of their careful transition from IV vasodilators and inotropes to oral therapy, suggests an early experience of fewer than 2 dozen cases. Continue reading →

INTRODUCTION: ST-segment elevationmyocardial infarction(STEMI) is a time-sensitive entity that has been shown to benefit from prehospital diagnosis by electrocardiogram (ECG). Current computer algorithms with binary decision making are not accurate enough to be relied on for cardiac catheterization lab (CCL) activation. Continue reading →

PARIS Obese patients with type 2 diabetes who underwent bariatric (metabolic) surgery were less likely than similar patients who received medical treatment to experience one of six major adverse cardiovascular events (MACE), findings of a new observational study show. Compared with obese patients with type 2 diabetes who received medical treatment, those who underwent bariatric surgery were 39% less likely to die from any cause or to develop heart failure, coronary artery events, cerebrovascular events, atrial fibrillation, or nephropathy in the following 8 years, Ali Aminian MD, bariatric surgeon at the Cleveland Clinic, in Ohio, reported here in a late-breaking science session of the European Society of Cardiology (ESC) Congress 2019, World Congress of Cardiology. The study was simultaneously published online September 2 in JAMA Continue reading →

Evidence-based medicine, it seems commonsensical; who could argue about using the best evidence available to make treatment decisions? The difficulty, of course, is that the evidence comes from studies of large populations, often expressed in terms of average responses; and as a clinician, you want to tailor the care to the one member of the population in front of you, your patient. Continue reading →

PHILADELPHIA There's sunny news, potentially, for patients with heart failure who are keen on cannabis. Hospitalized patients with a primary diagnosis of acute heart failure (HF) who say they are marijuana users are more likely to survive to discharge than nonusers, and they stay fewer days at less cost to the hospital, an observational study suggests Continue reading →

Top-line results projected to be available on or about September 30, 2019 Number of MACE increases from 250 to greater than 275 CALGARY, Alberta, Sept. Continue reading →

September has been a relatively slow month for the U.S. Food and Drug Administration (FDA) Continue reading →

Ventricular tachycardia is a life threatening heart condition in which arrhythmic heart beats occur in the ventricles. The two lower chambers of the heart are known as ventricles Continue reading →